Essex Woodlands Management, Inc. Revance Therapeutics, Inc. Transaction History
Essex Woodlands Management, Inc.
- $306 Million
- Q2 2024
A detailed history of Essex Woodlands Management, Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Essex Woodlands Management, Inc. holds 457,085 shares of RVNC stock, worth $1.17 Million. This represents 0.38% of its overall portfolio holdings.
Number of Shares
457,085
Previous 457,085
-0.0%
Holding current value
$1.17 Million
Previous $2.25 Million
47.78%
% of portfolio
0.38%
Previous 0.65%
Shares
7 transactions
Others Institutions Holding RVNC
# of Institutions
200Shares Held
81.3MCall Options Held
490KPut Options Held
143K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.99MShares$15.4 Million0.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...